查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916721

个人化癌症治疗市场预测至2032年：按产品、癌症类型、技术、最终用户和地区分類的全球分析

Personalized Oncology Market Forecasts to 2032 - Global Analysis By Product (Diagnostic Tests, Targeted Therapies, Companion Diagnostics, Biomarkers, Personalized Vaccines and Other Products), Cancer Type, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球个人化癌症治疗市场价值将达到 1,183.8 亿美元，到 2032 年将达到 2,277.8 亿美元，在预测期内的复合年增长率为 9.8%。

个人化癌症治疗是一种基于精准医学的癌症治疗方法，它根据个体独特的基因、分子和细胞特征来客製化治疗方法。透过分析肿瘤生物标记、基因突变和患者特异性特征，临床医生可以选择最有效的标靶治疗、免疫疗法或联合治疗，同时最大限度地减少副作用。这种策略可以改善治疗效果，提高病人安全性，并支持早期发现和监测。个人化癌症治疗标誌着从传统的「一刀切」式治疗模式转向精准医学的转变，为更有效、以患者为中心的癌症治疗带来了希望。

全球癌症负担日益加重

全球癌症发生率和盛行率的不断上升是推动个人化癌症治疗市场发展的主要因素。随着人口老化、生活方式改变和环境因素导致癌症病例增加，人们对精准、高效且个人化的治疗方案的需求也日益增长。个人化癌症治疗能够根据肿瘤的基因和分子特征进行标靶治疗，从而改善临床疗效和患者生活品质。日益加重的癌症负担正推动全球医疗保健系统加强对先进诊断技术、基因组学和治疗创新领域的投资。

医疗成本不断上涨

个人化癌症治疗的高昂费用是限制市场成长的主要阻碍因素。先进的诊断程序、基因组分析和标靶治疗通常需要大量资金，限制了患者的就医途径，尤其是在中低收入地区。此外，漫长的治疗方案和专业的医疗基础设施也加重了医疗服务提供者的经济负担。这些高支出可能会减缓治疗方法的普及，限制患者的就医范围，并造成治疗缺口。

基因组学和分子诊断的进展

基因组学和分子诊断技术的快速发展为市场带来了巨大的成长机会。次世代定序、液态生物检体和生物标记分析等创新技术能够实现早期检测和精准治疗方案的选择。这些技术进步有助于制定个人化治疗策略并最大限度地减少副作用。人工智慧 (AI) 与生物资讯学的融合将进一步提升预测能力，提高个人化癌症治疗的效率和临床疗效，并拓展其在全球各类癌症类型和医疗保健系统中的应用潜力。

监管和核准的挑战

监管的复杂性和严格的核准流程对市场构成重大威胁。新型治疗方法和诊断工具必须经过严格的临床试验，并符合各种国际监管标准，这可能会延缓产品上市。不同地区的核准时间差异，以及生物标记驱动疗法指南的不断更新，都给研发人员和投资者带来了不确定性。这些挑战增加了研发成本，并可能延缓产品上市，即使这些创新治疗方法具有临床前景和变革癌症治疗的潜力，患者也可能无法及时获得治疗。

新冠疫情的感染疾病

新冠疫情扰乱了个人化癌症治疗市场，导致全球范围内的临床试验、常规诊断和择期癌症治疗均出现延误。医疗资源被调配用于应对疫情，影响了病患招募、治疗实施和检查室运作。供应链中断进一步影响了诊断试剂盒和治疗药物的供应。然而，疫情也加速了远端医疗、远距监测和数位健康工具的普及，凸显了建构具有韧性的医疗基础设施的必要性。

预计在预测期内，基因组学将占据最大的市场规模。

由于基因组学在识别基因突变和肿瘤特征方面发挥关键作用，预计在预测期内，基因组学领域将占据最大的市场份额。包括次世代定序和全基因组分析在内的基因组学技术，为精准治疗方法的选择和治疗监测提供了至关重要的资讯。随着临床医生越来越依赖基因数据指南标靶治疗和免疫治疗，对基因组学服务的需求正在蓬勃发展。持续的技术创新和定序成本的下降，使基因组学成为推动整体市场发展的关键因素。

预计在预测期内，诊断检查室细分市场将呈现最高的复合年增长率。

由于对专业检测服务的需求不断增长，预计诊断检查室领域在预测期内将实现最高成长率。这些检查室发挥着至关重要的作用，包括进行生物标记分析以指导标靶治疗的选择。精准医疗意识的不断提高，以及对先进诊断基础设施的投资，正在推动市场扩张。癌症发生率的上升和早期检测策略的普及进一步刺激了需求，使诊断检查室成为个人化癌症治疗生态系统中快速成长且不可或缺的一部分。

比最大的地区

亚太地区预计将在预测期内保持最大的市场份额，这主要得益于该地区癌症发病率的上升、医疗基础设施的不断完善以及对先进癌症治疗投资的持续增长。精准医疗意识的提高、政府为加强癌症治疗而采取的措施以及基因组和分子诊断技术的普及，都推动了市场成长。此外，大规模的患者群体以及标靶治疗的日益普及，使亚太地区成为个人化癌症治疗创新和临床应用的关键市场中心。

年复合成长率最高的地区

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于其先进的医疗基础设施和对创新治疗方法的早期应用。该地区受益于基因组学、生物标记发现和精准医疗计画的巨额投资，以及能够加快核准的法规结构。患者意识的提高、尖端诊断技术的广泛应用以及製药公司与研究机构之间的密切合作，正在推动市场成长，使北美成为个人化癌症治疗的领先中心。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测以及复合年增长率（註：可行性需确认）。
  • 竞争标竿分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟进行基准分析

目录

第一章执行摘要

第二章 前言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球个人化癌症治疗市场（依产品划分）

  • 诊断测试
  • 标靶治疗
  • 伴随诊断
  • 生物标誌物
  • 个人化疫苗
  • 其他的

6. 全球个人化癌症治疗市场（依癌症类型划分）

  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 血癌
  • 其他的

7. 全球个人化癌症治疗市场（依技术划分）

  • 基因组学
  • 蛋白质体学
  • 次世代定序（NGS）
  • 生物资讯学

8. 全球个人化癌症治疗市场（依最终用户划分）

  • 医院和诊所
  • 诊断检查室
  • 研究所
  • 药局和零售店
  • 其他的

9. 全球个人化癌症治疗市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十一章 企业概况

  • Roche
  • Novartis
  • Pfizer
  • Merck &Co.
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Amgen
  • Bayer
  • AbbVie
  • Johnson &Johnson
  • Takeda
  • Illumina
  • Qiagen
  • Tempus AI
Product Code: SMRC33294

According to Stratistics MRC, the Global Personalized Oncology Market is accounted for $118.38 billion in 2025 and is expected to reach $227.78 billion by 2032 growing at a CAGR of 9.8% during the forecast period. Personalized oncology is a precision-driven approach to cancer treatment that tailors therapies based on an individual's unique genetic, molecular, and cellular profile. By analyzing tumor biomarkers, gene mutations, and patient-specific characteristics, it enables clinicians to select targeted therapies, immunotherapies, or combination treatments that are most effective while minimizing adverse effects. This strategy improves treatment outcomes, enhances patient safety, and supports early detection and monitoring. Personalized oncology represents a shift from traditional one-size-fits-all approaches toward precision medicine, offering hope for more effective, patient-centric cancer care.

Market Dynamics:

Driver:

Rising Global Cancer Burden

The increasing incidence and prevalence of cancer worldwide is a key driver for the personalized oncology market. As cancer cases rise due to aging populations, lifestyle changes, and environmental factors, there is a growing demand for precise, effective, and individualized treatment options. Personalized oncology enables targeted therapies based on genetic and molecular tumor profiles, improving clinical outcomes and patient quality of life. This rising cancer burden fuels investments in advanced diagnostics, genomics, and therapeutic innovations across global healthcare systems.

Restraint:

High Treatment Costs

The high costs associated with personalized oncology therapies present a significant restraint to market growth. Advanced diagnostic procedures, genomic sequencing, and targeted treatments often require substantial financial resources, limiting accessibility for patients, particularly in low- and middle-income regions. Additionally, prolonged treatment regimens and specialized healthcare infrastructure increase economic burdens on healthcare providers. These high expenditures can slow adoption, reduce patient reach, and create disparities in treatment availability.

Opportunity:

Advances in Genomics & Molecular Diagnostics

Rapid advancements in genomics and molecular diagnostics offer substantial growth opportunities for the market. Innovations such as next-generation sequencing, liquid biopsies, and biomarker profiling enable early detection and precise therapy selection. These technological developments allow for tailored treatment strategies and minimizing adverse effects. The integration of artificial intelligence and bioinformatics further enhances predictive capabilities, making personalized oncology more efficient and clinically impactful, while expanding its potential across diverse cancer types and global healthcare systems.

Threat:

Regulatory & Approval Challenges

Regulatory complexities and stringent approval processes pose a critical threat to the market. New therapies and diagnostic tools must undergo rigorous clinical trials and comply with diverse international regulatory standards, which can delay market entry. Variations in approval timelines across regions, coupled with evolving guidelines for biomarker-driven treatments, create uncertainty for developers and investors. Such challenges increase development costs and may slow adoption, hindering timely patient access to innovative therapies despite their clinical promise and potential to transform cancer care.

Covid-19 Impact:

The Covid-19 pandemic disrupted the personalized oncology market by delaying clinical trials, routine diagnostics, and elective cancer treatments worldwide. Healthcare resources were redirected toward pandemic management, affecting patient enrollment, therapy administration, and laboratory operations. Supply chain interruptions further impacted the availability of diagnostic kits and therapeutic agents. However, the pandemic also accelerated the adoption of telemedicine, remote monitoring, and digital health tools, highlighting the need for resilient healthcare infrastructure.

The genomics segment is expected to be the largest during the forecast period

The genomics segment is expected to account for the largest market share during the forecast period, due to its pivotal role in identifying genetic mutations and tumor profiles. Genomic technologies, including next-generation sequencing and whole-genome analysis, provide critical insights for precision therapy selection and treatment monitoring. As clinicians increasingly rely on genetic data to guide targeted therapies and immunotherapies, demand for genomic services is surging. Continuous innovation, combined with declining sequencing costs, positions the genomics as a central growth driver across markets.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diagnostic laboratories segment is predicted to witness the highest growth rate, due to rising need for specialized testing services. These laboratories perform critical functions, including biomarker analysis, which guide targeted therapy selection. Growing awareness of precision medicine, coupled with investments in advanced diagnostic infrastructure fuels market expansion. The increasing prevalence of cancer and adoption of early detection strategies further amplify demand, establishing diagnostic laboratories as a rapidly growing and indispensable component of the personalized oncology ecosystem.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's growing cancer prevalence, expanding healthcare infrastructure, and increasing investments in advanced oncology treatments. Rising awareness of precision medicine, government initiatives to enhance cancer care, and improving accessibility to genomic and molecular diagnostics contribute to market growth. Additionally, the presence of a large patient population, coupled with increasing adoption of targeted therapies, positions Asia Pacific as a significant market hub for personalized oncology innovations and clinical applications.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure and early adoption of innovative therapies. The region benefits from significant investments in genomics, biomarker discovery, and precision medicine programs, supported by regulatory frameworks that facilitate rapid approvals. High patient awareness, widespread use of cutting-edge diagnostic technologies, and strong collaborations between pharmaceutical companies and research institutions drive market growth, making North America a leading hub for personalized oncology.

Key players in the market

Some of the key players in Personalized Oncology Market include Roche, Novartis, Pfizer, Merck & Co., AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Amgen, Bayer, AbbVie, Johnson & Johnson, Takeda, Illumina, Qiagen and Tempus AI.

Key Developments:

In January 2026, Pfizer and Cartography Biosciences forged a multi-year collaboration to use Cartography's ATLAS and SUMMIT discovery platforms to pinpoint tumor-selective antigens for future cancer therapies, with Pfizer funding research and holding development and commercialization rights.

In December 2025, Pfizer struck an exclusive global collaboration and license deal with YaoPharma to develop, manufacture, and commercialize YP05002, an oral GLP 1 weight management agent, advancing its cardiometabolic pipeline with upfront and milestone payments and potential worldwide impact.

Products Covered:

  • Diagnostic Tests
  • Targeted Therapies
  • Companion Diagnostics
  • Biomarkers
  • Personalized Vaccines
  • Other Products

Cancer Types Covered:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Hematological Cancers
  • Other Cancer Types

Technologies Covered:

  • Genomics
  • Proteomics
  • Next-Generation Sequencing (NGS)
  • Bioinformatics

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmacies & Retail
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Oncology Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostic Tests
  • 5.3 Targeted Therapies
  • 5.4 Companion Diagnostics
  • 5.5 Biomarkers
  • 5.6 Personalized Vaccines
  • 5.7 Other Products

6 Global Personalized Oncology Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Lung Cancer
  • 6.4 Colorectal Cancer
  • 6.5 Prostate Cancer
  • 6.6 Hematological Cancers
  • 6.7 Other Cancer Types

7 Global Personalized Oncology Market, By Technology

  • 7.1 Introduction
  • 7.2 Genomics
  • 7.3 Proteomics
  • 7.4 Next-Generation Sequencing (NGS)
  • 7.5 Bioinformatics

8 Global Personalized Oncology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Laboratories
  • 8.4 Research Institutes
  • 8.5 Pharmacies & Retail
  • 8.6 Other End Users

9 Global Personalized Oncology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Roche
  • 11.2 Novartis
  • 11.3 Pfizer
  • 11.4 Merck & Co.
  • 11.5 AstraZeneca
  • 11.6 Bristol-Myers Squibb
  • 11.7 Eli Lilly
  • 11.8 Amgen
  • 11.9 Bayer
  • 11.10 AbbVie
  • 11.11 Johnson & Johnson
  • 11.12 Takeda
  • 11.13 Illumina
  • 11.14 Qiagen
  • 11.15 Tempus AI

List of Tables

  • Table 1 Global Personalized Oncology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Oncology Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Oncology Market Outlook, By Diagnostic Tests (2024-2032) ($MN)
  • Table 4 Global Personalized Oncology Market Outlook, By Targeted Therapies (2024-2032) ($MN)
  • Table 5 Global Personalized Oncology Market Outlook, By Companion Diagnostics (2024-2032) ($MN)
  • Table 6 Global Personalized Oncology Market Outlook, By Biomarkers (2024-2032) ($MN)
  • Table 7 Global Personalized Oncology Market Outlook, By Personalized Vaccines (2024-2032) ($MN)
  • Table 8 Global Personalized Oncology Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 9 Global Personalized Oncology Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 10 Global Personalized Oncology Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 11 Global Personalized Oncology Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 12 Global Personalized Oncology Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 13 Global Personalized Oncology Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 14 Global Personalized Oncology Market Outlook, By Hematological Cancers (2024-2032) ($MN)
  • Table 15 Global Personalized Oncology Market Outlook, By Other Cancer Types (2024-2032) ($MN)
  • Table 16 Global Personalized Oncology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Personalized Oncology Market Outlook, By Genomics (2024-2032) ($MN)
  • Table 18 Global Personalized Oncology Market Outlook, By Proteomics (2024-2032) ($MN)
  • Table 19 Global Personalized Oncology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 20 Global Personalized Oncology Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 21 Global Personalized Oncology Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Personalized Oncology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 23 Global Personalized Oncology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 24 Global Personalized Oncology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 25 Global Personalized Oncology Market Outlook, By Pharmacies & Retail (2024-2032) ($MN)
  • Table 26 Global Personalized Oncology Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.